Ide-Cel Shows Real-World Efficacy in CNS Multiple Myeloma
Real-world data showed ide-cel was active in patients with central nervous system manifestations of multiple myeloma.
Related Articles
ICIs Result in Increased Rates of High-Grade irAEs for Older Patients With Breast Cancer
The risk of developing high-grade immune-related AEs was heightened among patients with breast cancer who were older and who had chronic kidney disease.
FDA Approves Cosibelimab for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative…
Olaparib, Bevacizumab Combination Safe in Older Patients With Ovarian Cancer – Oncology Nurse Advisor
Adding olaparib to bevacizumab was safe with good quality of life in older patients with advanced ovarian cancer.
Patients With Advanced Breast Cancer May Have Higher Risk of Cardiovascular Disease
Researchers found an association between cardiovascular disease and more advanced stage of breast cancer at diagnosis, “independent of factors associated with delayed diagnosis and shared…
Effective and Well-Tolerated Combo in ER+/HER2– Metastatic Breast Cancer
Hope S. Rugo, MD, FASCO, discusses how the combination of elacestrant and abemaciclib compares with other treatment options for patients with advanced breast cancer, whether…
JAB-8263 Monotherapy Demonstrates Early Promise in Myelofibrosis
JAB-8263 given at once-daily doses ranging from 0.125 mg to 0.3 mg proved to be well tolerated in patients with myelofibrosis.
Plasma cell and cancer stem cell crosstalk in glioblastoma
Plasma cells (PCs) are the main producers of antibodies and have context-dependent roles in tumor immunity. In this issue of Cancer Cell, Gao et al. report…
Blocking a cancer escape hatch
Fred Hutch graduate student Adam Nguyen has won a F31 training award from the NIH to study a complex molecule called Tie2 that aids and…
Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding
Gao et al. show that the plasma cells (PCs) can be recruited to glioblastoma stem cell (GSC) niches via the CCL2-CCR2 chemokine program and promote glioblastoma…
Recurrence-Free Interval Is Longer With Low ctDNA Levels at Baseline in TNBC
ctDNA was most frequently detected within 6 months post-treatment in patients with TNBC, aligning with the early recurrence pattern characteristic of the disease.